Dr. Dufton brings over 25 years of clinical research and development experience, primarily focused on cardiovascular and pulmonary diseases. Prior to joining InCarda, Chris was Vice-President of Clinical Development at ARCA biopharma, where he led development of a genetically targeted therapy for atrial fibrillation in patients with heart failure. He also served as Director of Clinical Research at Gilead Sciences, where he led a cross-functional team responsible for Phase 4 development of Letairis® (ambrisentan) for pulmonary hypertension and idiopathic pulmonary fibrosis.
Prior to joining Gilead, he directed the ambrisentan program at Myogen, where he oversaw Phase 1-3 development leading to the accelerated approval of Letairis® for the treatment of pulmonary hypertension. Earlier in his career, he conducted oncology research at the University of Colorado Hospital/Medical School. Dr. Dufton has also been a consultant to the biopharmaceutical industry for such clients as Genentech and United Therapeutics.
Dr. Dufton received his Ph.D. in molecular and cellular biology from the University of Colorado and holds a B.A. degree in biochemistry from Rutgers University.